Literature DB >> 3145871

In vitro activity of new antibiotics against Haemophilus influenzae.

K Machka1, H Balg, I Braveny.   

Abstract

The activity of sulbactam/ampicillin, aztreonam, cefetamet, cefixime, ciprofloxacin, enoxacin, fleroxacin and ofloxacin was determined against 160 Haemophilus influenzae strains using a standardized microdilution method. The strains were categorized into four groups according to beta-lactamase production and their resistance to ampicillin, chloramphenicol, erythromycin, tetracycline and cotrimoxazole. All isolates tested, regardless of their beta-lactamase production or resistance to the above mentioned drugs, were susceptible to the nine antibiotics. The most active antimicrobial agents were aztreonam, cefixime, and the two quinolone derivatives ciprofloxacin and ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145871     DOI: 10.1007/bf01975058

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  In vitro susceptibility of Haemophilus influenzae to cefixime.

Authors:  M Powell; J D Williams
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  Chloramphenicol resistance in Haemophilus influenzae.

Authors:  A Manten; B van Klingeren; M Dessens-Kroon
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

3.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

4.  [Prevalence of antibiotic resistance of Haemophilus influenzae isolated in France: a year of activities of the network of surveillance for H. influenzae infections].

Authors:  H Dabernat; C Delmas; M B Lareng
Journal:  Pathol Biol (Paris)       Date:  1986-05

5.  Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones; T L Gavan
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec

6.  Distribution and resistance patterns of Haemophilus influenzae: a European cooperative study.

Authors:  K Machka; I Braveny; H Dabernat; K Dornbusch; E Van Dyck; F H Kayser; B Van Klingeren; H Mittermayer; E Perea; M Powell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

7.  Comparative bactericidal activity of cefixime, carumonam, enoxacin and roxithromycin with those of other antibiotics against resistant Haemophilus influenzae including beta-lactam tolerant strains.

Authors:  M G Bergeron; G Y Lavoie; F D Boucher
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

8.  Ampicillin-resistant Haemophilus influenzae type B possessing a TEM-type beta-lactamase but little permeability barrier to ampicillin.

Authors:  A A Medeiros; T F O'Brien
Journal:  Lancet       Date:  1975-03-29       Impact factor: 79.321

9.  Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.

Authors:  P M Mendelman; D O Chaffin; T L Stull; C E Rubens; K D Mack; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

10.  National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.

Authors:  G V Doern; J H Jorgensen; C Thornsberry; D A Preston; T Tubert; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

  10 in total
  5 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

3.  [In-vitro activity of enoxacin: a multicenter study].

Authors:  B Wiedemann; D Adam; A Bauernfeind; C Blasius; I Braveny; F Daschner; H Grimm; H Hahn; H Langmaack; F Ley
Journal:  Infection       Date:  1989       Impact factor: 3.553

Review 4.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

5.  Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.

Authors:  D R Nash; C Flanagan; L C Steele; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.